

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

LAPSE OF PLACING AGREEMENT

Reference is made to the announcements of the Huakang Biomedical Holdings Company Limited (the “**Company**”) dated 20 June 2022 and 8 July 2022 (the “**Announcements**”) in relation to the Placing Agreement and the Third Supplemental Placing Agreement (the “**Placing Agreements**”) entered into between the Company and the Placing Agent in respect of the Placing. Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as set out in the Announcements.

The Board announces that as the conditions under the Placing Agreements were not fulfilled on or before 22 July 2022, being the Long Stop Date in relation to the Placing, the Placing Agreements have lapsed and shall cease and terminate and none of the parties under the Placing Agreements shall have any claim against the other in relation to the Placing, save in respect of any antecedent breach of any obligation under the Placing Agreements.

The Board are of the view that the lapse of the Placing Agreements has no material adverse impact on the operation and financial position of the Company as a whole.

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 22 July 2022

As at the date of this announcement, the executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the independent non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary and Mr. Chan Kin Sang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.